Literature DB >> 1705624

The angiotensin II receptor and the actions of angiotensin II.

M J Peach1, D E Dostal.   

Abstract

Angiotensin II (Ang II) is a potent effector peptide of the renin-angiotensin system that exerts a wide variety of physiological actions on the cardiovascular, renal, endocrine, and central and peripheral nervous systems. Angiotensin exerts its actions by binding to specific receptors in the plasma membrane of various tissues. Structure-activity relationship studies and competition-binding experiments have identified a potency series of angiotensin analogues. Such studies have demonstrated that target organs display different preferences for Ang II and homologues such as Ang III and des-[Phe8] angiotensin II. Similarly, agents that normally are considered to be pure receptor antagonists for a given response (tissue) are full agonists in other tissues. Indirect evidence obtained from the above studies have led to the speculation that there are multiple angiotensin receptor subtypes among various tissues as well as within single cell types. Multiple mechanisms of signal transduction have been demonstrated for angiotensin. For example, depending on the effector organ, angiotensin stimulates phosphoinositide turnover and release of internal calcium, modulates voltage-dependent calcium channels, directly activates calcium channels, and inhibits adenylate cyclase activity. Recently, the identification of selective, high-affinity peptide and nonpeptide antagonists has resulted in further characterization of angiotensin receptors into distinct subtypes. In addition, dithiothreitol, an agent that reduces disulfide bridges, has been a useful tool in the characterization of angiotensin receptors as the subtypes apparently are not affected equally by this agent. However, further work needs to be performed to characterize angiotensin receptors with respect to heterogeneity, structure, transducing mechanisms, and physiological function.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1705624     DOI: 10.1097/00005344-199016004-00007

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  A haplotype of angiotensin receptor type 1 associated with human hypertension increases blood pressure in transgenic mice.

Authors:  Sudhir Jain; Alicia Prater; Varunkumar Pandey; Anita Rana; Nitin Puri; Ashok Kumar
Journal:  J Biol Chem       Date:  2013-11-07       Impact factor: 5.157

2.  Key role of P38 mitogen-activated protein kinase and the lipoxygenase pathway in angiotensin II actions in H295R adrenocortical cells.

Authors:  Rama Natarajan; Dong-Chang Yang; Linda Lanting; Jerry L Nadler
Journal:  Endocrine       Date:  2002-08       Impact factor: 3.633

3.  Angiotensin II receptor antagonists (AT1-blockers, ARBs, sartans): similarities and differences.

Authors:  P A van Zwieten
Journal:  Neth Heart J       Date:  2006-11       Impact factor: 2.380

4.  Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells. Correlation with the expression of specific endogenous growth factors and reversal by suramin.

Authors:  H Weber; D S Taylor; C J Molloy
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

5.  Angiotensin II induces tyrosine phosphorylation of insulin receptor substrate 1 and its association with phosphatidylinositol 3-kinase in rat heart.

Authors:  M J Saad; L A Velloso; C R Carvalho
Journal:  Biochem J       Date:  1995-09-15       Impact factor: 3.857

6.  Stimulation of two vascular smooth muscle-derived cell lines by angiotensin II: differential second messenger responses leading to mitogenesis.

Authors:  C Morton; R Baines; I Masood; L Ng; M R Boarder
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

Review 7.  Kidney Is Essential for Blood Pressure Modulation by Dietary Potassium.

Authors:  Xiao-Tong Su; Chao-Ling Yang; David H Ellison
Journal:  Curr Cardiol Rep       Date:  2020-08-13       Impact factor: 2.931

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.